Biorestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Update

Biorestorative Therapies, Inc. (NASDAQ:BRTX) was the recipient of a significant growth in short interest during the month of March. As of March 13th, there was short interest totaling 1,318,064 shares, a growth of 67.5% from the February 26th total of 787,086 shares. Based on an average trading volume of 18,854,732 shares, the days-to-cover ratio is presently 0.1 days. Currently, 21.1% of the company’s shares are short sold.

Hedge Funds Weigh In On Biorestorative Therapies

Institutional investors and hedge funds have recently made changes to their positions in the business. Citadel Advisors LLC acquired a new stake in Biorestorative Therapies in the third quarter valued at $152,000. DRW Securities LLC bought a new stake in shares of Biorestorative Therapies in the 4th quarter worth about $55,000. Finally, Virtu Financial LLC raised its stake in shares of Biorestorative Therapies by 102.4% in the 3rd quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock valued at $35,000 after purchasing an additional 12,319 shares in the last quarter. 69.38% of the stock is currently owned by hedge funds and other institutional investors.

Biorestorative Therapies Price Performance

Shares of BRTX stock opened at $0.30 on Friday. The company’s fifty day moving average price is $0.54 and its two-hundred day moving average price is $1.06. The firm has a market capitalization of $2.69 million, a P/E ratio of -0.19 and a beta of 0.47. Biorestorative Therapies has a 12 month low of $0.19 and a 12 month high of $2.05.

Biorestorative Therapies (NASDAQ:BRTX) last announced its earnings results on Thursday, March 26th. The company reported ($0.37) earnings per share for the quarter, meeting the consensus estimate of ($0.37). Biorestorative Therapies had a negative return on equity of 331.61% and a negative net margin of 3,956.11%.The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.15 million. On average, sell-side analysts anticipate that Biorestorative Therapies will post -1.43 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biorestorative Therapies in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Biorestorative Therapies presently has an average rating of “Sell”.

About Biorestorative Therapies

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.